Introduction
Noribogaine (Fig. 1) is the primary human metabolite of ibogaine (Obach et al., 1998) , an alkaloid derived from the African shrub, iboga (Tabernanthe iboga). The therapeutic and oneirophrenic properties of iboga roots are known for centuries in Equatorial Africa where iboga continues to be used as natural medicine and for ceremonial purposes (Goutarel et al., 1993; Samorini, 1995) . Naranjo, in collaboration with Bocher, issued a patent in 1969 based on 54 clinical cases featuring the usefulness of ibogaine for psychotherapy and anti-drug purposes (Bocher and Naranjo, 1969) . A few decades later, the benefits of iboga (ibogaine) in the treatment of addiction for multiple drugs of abuse were highlighted by different groups (Alper et al., 1999; Sheppard, 1994) . Preclinical studies show that ibogaine is a polypharmacological drug that can reduce self-administration to many drugs of abuse in rodents, including cocaine, morphine, heroin, alcohol, and nicotine; and further experimentation in humans supported its usefulness to treat addiction (Alper, 2001; Baumann et al., 2001a; Freedlander, 2003; Maciulaitis et al., 2008; Mash et al., 2000; Popik et al., 1995) .
Noribogaine displayed a slow pharmacokinetic clearance rate in humans, being detected for several days in blood after ibogaine ingestion, and was proposed to be responsible for many of the human in vivo effects seen after ibogaine therapy (Mash et al., 2000) . Noribogaine produced ibogaine-like anti-addictive effects in animals and the systemic administration of noribogaine induced long-lasting decrease of morphine and cocaine self-administration Mash and Schenk, 1996) . Noribogaine also decreased ethanol self-administration (Rezvani et al., 1995) and nicotine self-administration in rats (Chang et al., 2015) . The brain levels of noribogaine in female/male rats were approximately 20/ 13, 10/7 and 0.8/0.1 mM at 1, 5, and 19 h after intra-peritoneal injection of 40 mg/kg ibogaine whereas plasma levels were 10e20 fold less (Pearl et al., 1997) . This indicated that noribogaine had excellent drug permeability across the bloodebrain barrier and reached high levels in the brain. Unlike ibogaine, noribogaine did not produce tremors and ataxia in rodents (Baumann et al., 2001b) , suggesting that it is better tolerated than its parent compound and a better drug candidate for clinical development. Recently, a study performed in healthy volunteers indicated that single oral doses of noribogaine from 3 to 60 mg were safe and well tolerated (Glue et al., 2015) .
Of particular interest with regards to their acknowledged roles in modulating opiate dependence are ibogaine and noribogaine's effects on the opioid system. In addition to effects on the pursuit and administration of drug of abuse, these drugs were shown to modulate the analgesic power and the development of physical tolerance to morphine. Pre-administration of noribogaine (40 mg/ kg, 19 h) had a moderate but detectable effect of potentiation on both basal nociception and morphine-induced analgesia (Bagal et al., 1996) . When noribogaine (40 mg/kg) was co-administered with 4 mg/kg morphine, it amplified the duration of morphineinduced analgesia (Bagal et al., 1996) . Noribogaine (40 mg/kg) enhanced anti-nociception when added to morphine but did not enhance anti-nociception when combined with U50,488 (kappa opioid agonist) or DPDPE (delta opioid agonist) . At lower doses of 10e20 mg/kg, noribogaine has also been shown to greatly potentiate (or restore) morphine anti-nociceptive activity in morphine-tolerant mice but remained inactive in naïve mice (Sunder Sharma and Bhargava, 1998) . Finally, noribogaine was shown to prevent the development of tolerance to the analgesic effects of morphine . The mode of action for these effects, as well as the anti-addictive effects, remained largely uncharacterized thus far.
Noribogaine has principal known binding affinities to the opioid receptors, the nicotinic acetylcholine receptors (Maillet et al., submitted manuscript) , and the SERT and DAT transporters, but marginal affinities to NMDA, sigma 2 and 5-HT2 receptors in comparison to the parent compound ibogaine (Baumann et al., Agonists (red), partial agonists (purple), and antagonists (green) are arranged in the diagram according to their affinities for either the m or k opioid receptor. Structures in the overlapping region have affinity for both subtypes. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 2001a; Bowen et al., 1995; Mash et al., 1995a Mash et al., , 1995b Staley et al., 1996) . Ibogaine and noribogaine were found to have potencies in the micro-to high nano-molar range for the opioid receptors (Pearl et al., 1995) but they do not appear to be conventional opioid agonists or antagonists. Noribogaine, and ibogaine to a lesser extent, were shown to induce naloxone-sensitive GTPgS binding in rat brain preparations . These drugs however did not induce conditioned place preference like mu agonists or conditioned place aversion like kappa agonists or mu antagonists (Skoubis et al., 2001) in animals ( (Parker et al., 1995) and unpublished results). In addition, neither morphine nor the kappa agonist U50,488 substituted for the discriminative stimulus of noribogaine treatment in rats (Helsley et al., 1998) (Zubaran et al., 1999) . In a sense, noribogaine was neither a mu or a kappa opioid agonist or antagonist in vivo and it remained largely unclear what the specific roles and activities of noribogaine at the opioid receptors would be in relation to physiological outputs.
To address this gap of knowledge, we carried out a pharmacological study to characterize noribogaine to the mu (OPRM) and the kappa (OPRK) opioid receptors. We performed comprehensive in vitro and in silico experimental designs encompassing both binding and functional assays for G-protein signaling using GTPgS binding stimulation, b-arrestin signaling using protein recruitment assay, in addition to performing docking simulations. We then compared the pharmacology of noribogaine to its parent drug ibogaine, the synthetic indole alkaloid 18-methoxycoronaridine (18-MC) (Glick et al., 2000) , and a series a specific opioid ligands including the kappa partial agonist nalmefene (Bart et al., 2005) , and the biased kappa agonist 6 0 -GNTI (Rives et al., 2012) (Fig. 1) . Our study reveals an atypical biased agonism of noribogaine at the kappa receptors and provides important pharmacological basis for its mechanism of action as a drug therapeutic.
Materials and methods

Materials
[Phenyl-3, 4-3 H]-U-69,593 (43.6 Ci/mmol), 
Membrane preparation
Membrane preparations of rat midbrain tissues were purchased from Chantest (Cleveland, OH). Membrane preparation of human OPRK CHOeK1 cells were purchased from PerkinElmer Life Sciences (Boston, MA) and membranes of human OPRM CHOeK1 cells were prepared as described below. Adherent cells were harvested on ice, with cold PBS and a cell scraper, pelleted and frozen at À80 C overnight. Cell lysis was performed at 4 C in 50 mM Tris (pH 7), 2.5 mM EDTA and cOmplete protease inhibitor cocktail (cOmplete, F. Hoffmann-La Roche Ltd). Cells were homogenized with a polytron, centrifuged at 2500 rpm for 10 min at 4 C and the supernatant was recovered. The process was repeated once.
Supernatant was centrifuged at 21,000 rpm for 90 min at 4 C and pellets were re-suspended in 50 mM Tris (pH 7) and 0.32 M sucrose. Total protein concentration was determined using a ThermoScientific NanoDrop spectrophotometer or by Bradford assay. Membrane samples were stored at À80 C at 1e5 mg/mL protein concentration. Membranes from brain tissues were stored in 50 mM Tris (pH 7), 1 mM EDTA and 0.32 M sucrose with protease inhibitor cocktail.
Radioligand binding
Competitive binding experiments were performed using conditions recommended by the supplier (Perkin Elmer). Membranes were thawed on ice and diluted in binding buffer 50 mM Tris-HCl pH 7.4, 5 mM MgCl 2 at 5 mg of membrane per reaction. Competition binding assays were performed in 500 mL total volume con- (Toll et al., 1998) and carried out in a 96-well format. Cell membranes (10 mg per reaction) were incubated in a binding buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl 2 x6H 2 O, 0.2% bovine serum albumin, and GDP 10 mM, pH 7.4) containing 80 pM [ 35 S]GTPgS and varying concentrations of opioid agonists (U69,593, DAMGO, morphine, dynorphin A, nalmefene, or noribogaine) in a total volume of 100 mL for 60 min at 25 C.
Membranes were pre-incubated with the GDP for 15 min on ice prior to the addition of ligands. Antagonists were added to the membrane solution 20 min prior the addition of the agonist, and [ 35 S]GTPgS was added 5 min after the agonist. Non-specific and basal levels of GTPgS binding were evaluated by using 10 mM cold (control agonist) . For inhibitory ligands, e-signal was calculated using maximal level of inhibition (I max ) normalized from 0 (basal, buffer) to 1 (agonist without inhibitor).
Bias-coupling (quantification of pathway bias for the coupling efficiency) was calculated by dividing the EC 50 (activation bias) or the K e (inhibition bias) issued from the G-protein pathway assays by those issued from b-arrestin pathway assays for a given ligand, rectified by the intrinsic functional assay efficiency (defined as the average of the cluster values of functional coupling efficiency of typical full agonists and antagonists). The intrinsic functional assay efficiency is dependent of the assay and the experimental conditions (for instance the GDP content in the GTPgS assay, the temperature and time of incubation) and independent of the ligands binding affinity (the potency ranking of high to low affinity ligands remain constant regardless of the assay conditions). Bias-efficacy in favor of the G-protein pathway was evaluated by dividing the functional activation and the functional inhibition maximum responses (e-signal) from the G-protein pathway by the beta-arrestin pathway assays for a given ligand.
m-Opioid receptor noribogaine binding model
We used the mouse m-opioid receptor OPRM co-crystal structure available in the Protein Data Bank (PDB), PDB accession 4dkl, Uniprot accession P42866. The mouse OPRM has 94% (global) sequence identity to the corresponding human receptor (Uniprot accession P35372) and all residues in the binding site are identical. The receptor was crystallized as a fusion protein (OPRMeT4L) with an irreversible morphine antagonist ligand (bound to Lys233, PDB numbering). All simulations were performed using the Schrodinger 2014.2 and Desmond 2014.2 software suite. For initial docking studies we imported the PDB file into Maestro 9.5 (Schrodinger) and ran the standard protein preparation workflow to assign bond orders and clean up the structure including hydrogen bond optimization and constrained minimization. In the preparation process missing side chains were added using Prime. The fusion protein was manually cut and removed between residues Val262 and Glu270 to leave just the GPCR transmembrane domain; the cut residues were capped as primary amide (C-terminal) and acetate (N-terminal). A (non-covalent) ligand entry (separate from the chain) was manually created in Maestro. The resulting protein complex was again processed via the protein preparation workflow. A docking grid was created around the co-crystal ligand using Glide (standard settings). Several small molecules including the morphinan co-crystal ligand (unbound), ibogaine and noribogaine were imported as 2D SDF into Maestro and 3D structure representations were generated using LigPrep (default settings); two representations (inverted at the tertiary bridgehead nitrogen) were generated for each ligand. These were docked using Glide SP (standard settings except keeping 5 poses per compound out of 30 for post-minimization). The docked morphinan ligand reproduced the co-crystal almost perfectly. This docked complex was then optimized using Prime Refine ProteineLigand complex (default settings). This complex was then used to generate another docking grid using Glide (default settings around the ligand) followed by Glide SP docking of the prepared ligands. In these results, the top poses of noribogaine and ibogaine aligned well the morphinan antagonist (hydrophobic ibogaine and noribogaine bicyclic system and ethyl substituent with morphinan cyclopropyl residues and the positively charged tertiary amines, which all form a hydrogen bond to the site chain of Asp147). The m-OR noribogaine docking complex was then used in a 12 ns molecular dynamics (MD) simulation. The MD system generation and simulations were performed in Desmond using an all atom system with a membrane model and explicit water model (ASP). The Desmond software automatically sets up the systems (adjust charges, adds water molecules) and performs several rounds of minimization and short simulations before the 12 ns production run. MD was run on the Pegasus 2 cluster at the Center for Computational Science at the University of Miami (http://ccs. miami.edu/hpc/) using 48 processors and completed in less than 19 h. Simulation analysis was performed using the Desmond trajectory analysis software. A representative frame with these most prevalent interactions throughout the simulation was extracted from the trajectory, processed via protein preparation (including constrained minimization) to remove overlapping atoms, and visualized using PyMol. Table 1 ). Noribogaine exhibited the highest apparent affinity for OPRK with a K i value of 720 ± 128 nM. At OPRK, ibogaine displayed a K i of 3.68 ± 0.22 mM, while 18-MC had a K i a 1.84 ± 0.12 mM. At the OPRM, noribogaine displayed a K i of 1.52 ± 0.3 mM, while ibogaine and 18-MC K i values were 6.92 ± 0.83 mM and 2.26 ± 0.35 mM respectively. Values of both noribogaine and ibogaine for the human OPRM/K receptors were comparable to that of the calf OPRM and OPRK receptors (1.52 and 0.96 mM, Table 1 ) where noribogaine was also previously shown to have~30-fold less affinity at OPRD than at OPRK (Pearl et al., 1995) . In our assays, 18-MC had no OPRM preferential binding with a DpK i of 0.1, contrary to the previously reported 5-fold selectivity (DpK i ¼ À0.7) for OPRM over OPRK (Glick et al., 2000) . Experimental values, historical values from the literature, and control ligands, are displayed in Table 1 for agonists, partial agonists, and antagonists used in this study. Fig. 2A) . The prototypical full agonist, U69,593, and the endogenous ultra-potent agonist, dynorphin A, were used as controls for OPRK function. Calculated EC 50 and E Max values are enumerated in Table 2 (Fig. 2B , Table 2A ).
Results
Apparent binding affinities of noribogaine to OPRM and OPRK
Noribogaine is agonist of the OPRK G-protein pathway
Ibogaine displayed a notably lower agonist efficacy than noribogaine at OPRK with an E Max of 18 ± 1.4%, while 18-MC failed to stimulate [ 35 S]GTPgS binding to OPRK. In our assays, morphine and dynorphin A displayed E Max values of 91 ± 7% and 94 ± 7% respectively, and nalmefene, a partial agonist of OPRK, maximally stimulated at 35 ± 4.7%, which is similar to formally reported values (Bart et al., 2005) . Noribogaine stimulation of [ 35 S]GTPgS binding was also observed in membrane preparations from rat midbrain tissues and this signal was nor-BNI-sensitive, confirming the agonist activity of noribogaine in native brain tissues (data not shown).
The apparent coupling efficiencies of agonists DAMGO, U69,593, morphine, dynorphin A, nalmefene, 6 0 -GNTI, noribogaine and ibogaine at the G-protein pathway were calculated (pK i e pEC 50 ) and found to be congruent with EC 50 values shifted by~1 log in comparison to apparent affinity K i for all agonists (Tables 2A and 3 ). The activation coupling efficiency of dynorphin A (0.6, this work) and 6 0 -GNTI (0.2, (Schmid et al., 2013) ) were superior to other agonists in this assay, indicating that a lower fraction of bound receptors was sufficient to activate the pathway toward its maximal efficiency. Conversely, the hillslope for dynorphin A concentration response curves was below 1 (~0.7), indicating slower kinetics and probably a longer residence time in the receptor active conformations, producing the observed heightened coupling efficiency. Table 1 Binding affinity of noribogaine and other drugs at the human mu (OPRM) and kappa (OPRK) opioid receptors. K i values of noribogaine, ibogaine, and 18-MC (n ! 3). Values for control ligands morphine, naloxone DAMGO, U69,593, dynorphin A, [met]-enkephalin, nalmefene, and buprenorphine were determined and/or gathered from the literature. Specificity for the OPRK receptor was evaluated using the equation DpK i ¼ pK i (OPRK)-pK i (OPRM). Agonists (red), partial agonists (purple), and antagonists (green). (Huang et al., 2001 , Li et al., 1993 , Raynor et al., 1994 ).
Common kappa antagonists competitively compete with noribogaine
Inhibitory effects of kappa antagonists naloxone, nor-BNI, 18-MC, and the partial agonist nalmefene on the agonist-induced [ 35 S]GTPgS binding by full or partial agonists dynorphin A, U69,593, morphine, noribogaine and nalmefene were investigated. Concentration-response curve shifts of agonists were gathered in the absence and presence of fixed antagonist concentration (30 nM naloxone, 5 nM nor-BNI, 100 mM 18-MC, and 3 nM nalmefene) or in some instances with iterative concentrations of the antagonist (Fig. 2B, Table 3 ).
All antagonists tested right-shifted the concentration-response curves of noribogaine, dynorphin A, morphine or U69,593 in a concentration-dependent manner. This finding is consistent with these ligands being surmountable competitors of the noribogaine and other tested agonists' binding site. Functional inhibition constants (K e ) of the antagonists are shown in Table 3 with the assumption of ideal conditions of competitiveness and equilibrium. In all instances, the functional inhibition constants for these inhibitors were close to their K i , regardless of the agonist they were competing with, indicating that noribogaine was no different than other agonists tested.
Noribogaine is an atypically weak functional competitor of other kappa agonists in the [
S]GTPgS binding assay
Nalmefene is a partial agonist and can compete as a rival agonist against more efficacious agonists and inhibits their response up to the reduced efficacy of nalmefene itself, a pharmacologically . Coupling efficiency (e-coupling, e-cpl) indicated the relationship between the apparent binding affinity (K i ) versus the EC 50 or the functional inhibition potency (K e ) of a given ligand and used the equations p(Ki/EC 50 ) and p(Ki/K e ), where p represents a elog10 transformation.
[Ϟagonist] represents the agonist used to test inhibitory compounds. Outliers in comparison to reference compounds dynorphin A and U69,593 (activation), and nor-BNI and naloxone (inhibition) are underlined. Data are shown as the mean ± SE of (n) experiments. Table 2 . (B) EC 50 shifts of noribogaine and dynorphin A were produced by pre-incubating antagonists (naloxone: NALO; nalmefene: NALM; NorBNI) at 30, 3, and 5 nM respectively. Functional inhibition constants (K e ) of antagonists were calculated and are shown in Table 3 . Data points used for the non-linear regression analysis figures (A and B) are shown as the mean ± SEM of each representative experiment(s). coherent phenomenon also known as mixed agonism/antagonism property. Noribogaine was a partial agonist at OPRK in the [ 35 S] GTPgS binding stimulation assays (Fig. 2) . Therefore, we set out to determine if noribogaine was also a rival agonist that can functionally compete with and reduce the activity of more efficacious agonists than itself.
Dynorphin A and morphine concentration-response curves were performed in the presence and absence of rival agonists nalmefene or noribogaine at concentrations of 36-fold and 79-fold their respective K i (nalmefene 3 nM, noribogaine 50 mM) (Fig. 3A) . Nalmefene readily shifted the EC 50 of dynorphin A and morphine to the right, with a functional inhibition constant K e of 0.077 ± 0.016 nM and 0.11 ± 0.005 nM. Calculated K e were within a close range of the Ki (0.08 nM), similar to a competitive antagonist such as nor-BNI or naloxone (Table 3 , Fig. 3A) . Noribogaine, on the other hand, poorly shifted the EC 50 of these agonists and the K e estimates in these conditions were 40 ± 16 mM and 15 ± 4 mM respectively, about 40-fold its K i (Table 3, Fig. 3A) . Noribogaine against dynorphin A, U69,593, morphine, and nalmefene, was an outlier rival agonist in all instances compared to the typical partial agonist nalmefene and antagonists like naloxone, nor-BNI, and 18-MC (Table 3 , underlined values, Fig. 3C ). These data showed that noribogaine was an atypical partial kappa agonist because it was unable to functionally surmount receptor activation of other agonists of the OPRK G-protein pathway.
In another set of experiments (Fig. 3B ), noribogaine and nalmefene concentration-inhibition curves were produced in the presence of more efficacious agonists such as U69,593, dynorphin A, or morphine. In the case of nalmefene, noribogaine was used as the agonist. Nalmefene readily reduced the signal of moderate to high concentrations of rival full (U69,593) or partial (noribogaine) agonists to its own reduced levels (30%) with an apparent IC 50 Table 4 Bias quantification at the kappa and mu opioid receptors. E-coupling for activation and inhibition is a measure of the coupling efficiency, using pKi-pEC 50 and pKi-pK e , where p is elog10 transformation. Bias-coupling represents the relative preference of coupling between the G-protein or b-arrestin pathways and used the difference in e- proportional to the rival agonist concentration (including noribogaine) (Fig. 3B ) and a K e consistent with its K i (Table 3) . Noribogaine reduced the signal of more efficacious agonists to its own signal (70%), but the IC 50 values were high (100e300 mM range) and the calculated K e were consistent with poor functional inhibition. The apparent functional activation constant (apparent EC 50 ), of dynorphin A, U69,593 and morphine were then estimated in the presence of noribogaine or nalmefene (Table 3) . Apparent EC 50 for all agonists tested in the presence of nalmefene were close to their experimental EC 50 . However, in the presence of noribogaine, apparent EC 50 of common kappa agonists were significantly lower than their actual experimental EC 50 (Table 3 , underlined values). This atypical phenomenon may reflect the stabilization of a differential set of active receptor conformations by noribogaine compared to other kappa agonists tested. Altogether, these data suggest a potential protean agonism of noribogaine, a predictive functional bias (Kenakin, 2007) that we set to assess further.
Noribogaine is a G-protein-biased kappa agonist
PathHunter b-Arrestin GPCR assays detecting the interaction of b-arrestin 2 with the activated receptor were used to measure non-G protein OPRK activity in CHOeK1 live cells (Violin et al., 2014) . Concentration-response curves to noribogaine were compared to full endogenous agonist dynorphin A drug treatment (Fig. 4A) . Calculated EC 50 values, maximal responses and coupling efficiencies are shown in Table 2B . Dynorphin A displayed an EC 50 of 11 ± 2 nM at OPRK. Noribogaine exhibited a profound functional bias at OPRK and was marginally efficacious at inducing b-arrestin recruitment with an E Max of 13 ± 3% and an estimated EC 50 of 110 nM. For comparative purposes, nalmefene was tested once and displayed an E Max of 30% as expected for this unbiased partial agonist. EC 50 and E Max values from (Schmid et al., 2013) were collected for 6 0 -GNTI, and showed that noribogaine was activating at the same level as 6 0 -GNTI. Ibogaine and 18-MC were tested once; they did not display any bias and their pharmacological behavior was comparable to typical kappa ligands.
The functional activation coupling efficiencies in the b-arrestin assay were calculated in a similar manner as the [35S]GTPgS binding assay and showed that dynorphin A and U69,593 displayed a similar coupling efficiency of 2, reflecting the intrinsic assay efficiency (Table 2B , Fig. 4C ). Noribogaine had a negative activation coupling efficiency of À0.9 for the b-arrestin pathway, indicating a profound coupling bias of 1:630 in favor of this pathway in comparison to the G-protein pathway (Table 4 ). In comparison, the biased ligand 6 0 -GNTI did not display activation coupling bias between the G-protein and the b-arrestin pathways (Table 4) .
The activation efficacy bias between the G-protein pathway and the b-arrestin pathway was evaluated by comparing the maximal efficacy (E Max ) for each pathway in comparison to reference ligand dynorphin A or U69,593 (1e1 maximal efficacies ratio) (Table 4) . Although nalmefene is a partial agonist, it did not display an activation efficacy bias, reflecting that partial agonism is not an indication of bias per se. Both noribogaine and 6 0 -GNTI displayed an activation efficacy bias in favor of the G-protein pathway and noribogaine was almost twice more biased than 6 0 -GNTI (5.5e1 versus 3 to 1).
Noribogaine is a bÀarrestin-biased kappa antagonist
Because noribogaine was unable to induce the recruitment of barrestin following activation of the OPRK receptors, it was then tested for its ability to inhibit b-arrestin recruitment induced by efficacious agonists of this pathway (Fig. 4B) . In these assays, barrestin recruitment was induced by the endogenous agonist dynorphin A sets at its EC 80 concentration and challenged with increasing concentrations of noribogaine. Noribogaine inhibited dynorphin A-induced b-arrestin recruitment up to~60%, with an IC 50 of 1 ± 0.16 mM (Fig. 4B, Table 2B ). In contrast, when a similar noribogaine concentration-inhibition experiment was performed on the G-protein pathway with dynorphin A at its EC 80 , noribogaine only inhibited agonist-induced activation of the receptor by~5%
with an IC 50 of~150 mM (Fig. 4B) . Noribogaine was thus 150-fold more potent at inhibiting dynorphin A-induced b-arrestin 2 recruitment than at inhibiting dynorphin A-induced G-protein activation (Table 4) . For comparison, typical partial agonist nalmefene inhibited dynorphin A-induced b-arrestin recruitment up to 70% with an approximate K e of 0.32 nM, whereas it inhibited dynorphin A-induced GTP-binding with a K e of 0.08 nM and was apparently equipotent with only a 4-fold difference. Notably, the apparent inhibition coupling efficiencies for antagonists of the barrestin pathway were all clustered in a 0.5 range (Fig. 4C) and indicated that the current experimental conditions were producing an assay slightly less sensitive to antagonists than the GTP-binding assay (coupling efficiency close to 0) with a robust assay's intrinsic (A) CHOeK1 cell membrane preparations expressing the OPRK receptors were preincubated with the partial agonists nalmefene (NALM) and noribogaine (NORI), and the pure antagonist nor-BNI at 36-fold, 79-fold, and 125-fold their respective apparent affinity K i . Membrane preparations were then stimulated with increasing concentrations of dynorphin A (DYNA) and morphine (MOR). The functional inhibition constants K e were calculated and compared to the ligand's respective K i and EC 50 (GTPgS) as shown in Table 3 . (B) Membrane preparations were stimulated by increasing concentrations of NALM or NORI in the presence of agonists U69,593 (U69-100 nM), morphine (MOR-5 mM), noribogaine (NORI-10 and 100 mM) and nalmefene (NALM-20 nM). Dotted lines indicate the interval between the EC 50 and the IC 50 of tested ligand (NALM and NORI) in the absence and the presence of 100 nM U69,593. Data are shown as the mean ± SEM of representative experiment(s) performed in triplicate. (C) Representation of the G-protein pathway coupling activation efficiency (Àlog(K i /EC 50 )) of a series of kappa agonists and of the coupling inhibition efficiency (Àlog(K i /K e )) against dynorphin A (see Table 3 for other agonists) for a series of kappa antagonists and partial agonists. Clustering of data points represents the intrinsic assay efficiency in the current experimental conditions of [35S]GTPgS binding activation with CHO membranes expressing the human OPRK. Outlier data points indicate atypical pharmacology of certain ligands (noribogaine, 6 0 -GNTI).
coupling efficiency reproducibility. Finally, the inhibition efficacy bias for noribogaine was 1:2 in favor of the b-arrestin pathway, which is similar to 6 0 -GNTI (Table 4) , whereas other antagonists were unbiased.
3.7. Noribogaine has a marginal mu agonistic activity [ 35 S]GTPgS binding to membrane preparations of CHO cells stably expressing human OPRM were examined in response to noribogaine, ibogaine, and morphine drug treatment (Fig. 5A , Table 5A ). The prototypical full agonist DAMGO and the endogenous agonist [met]-enkephalin ([met]-Enk) were used as reference agonists. Morphine was a partial agonist with an E Max of 80 ± 4.5% and an EC 50 of 32 ± 1.2 nM. The partial agonist buprenorphine stimulated OPRM with an E Max of 26 ± 2.2% in our assays and in previously reported assays (Saidak et al., 2006) . Noribogaine marginally stimulated [ (Fig. 5A , Table 5A ) and comparable to the level of activation previously reported (Antonio et al., 2013) . Ibogaine and 18-MC did not stimulate the OPRM G-protein pathway. Concentration-response curves of barrestin recruitment of noribogaine at the OPRM receptors were compared to full agonist [met]-enkephalin (Fig. 5A). [Met]-enkephalin displayed an EC 50 of 159 ± 38 nM at OPRM. As expected given its marginal efficacy at the G-protein pathway, noribogaine was not a mu agonist of the b-arrestin pathway. Calculated EC 50 values, maximal responses and coupling efficiencies are shown in Table 5 .
Weak antagonistic properties of noribogaine at the mu opioid receptor
Noribogaine marginally stimulated [
S]GTPgS binding via
OPRM with an approximate EC 50 of 16 mM (Fig. 5A) . Therefore, we investigated if noribogaine was an antagonist of OPRM.
[Met]-enkephalin, DAMGO and morphine dose responses were carried out in the presence and absence of 15 and 150 mM of noribogaine ( Fig. 5C and D) . Noribogaine was an inhibitor of all agonists tested and shifted their EC 50 to the right by a magnitude of~1Àlog. The calculated functional inhibition constant (K e ) values were~20 mM (Table 5A, and Table 5 footer). In a similar design, naloxone displayed a K e of 1.2 ± 0.3 nM, a value close to its K i at OPRM, like its inhibition constant at OPRK (Tables 2 and 3) . On the contrary, noribogaine was an outlier antagonist with an inhibitory coupling efficiency of 1.1, while ibogaine, naloxone, and 18-MC were still behaving like typical antagonists with clustered e-coupling values close to 0 (Fig. 5C and Table 5A ). Noribogaine was then tested for its ability to inhibit [met]-enkephalin-induced b-arrestin-2 recruitment at OPRM (Fig. 5B and Table 5B ). Noribogaine inhibited agonist responses by 80e100% with an IC 50 of 100 ± 25 mM.
Regardless of the pathway tested (G-protein and b-arrestin pathways), noribogaine displayed similar functional inhibition constants and was an unbiased ligand of the mu opioid receptor (Table 4) , albeit an inhibitory coupling efficiency outlier (Table 5A / B) in comparison to other mu antagonists. In fact, noribogaine also decreased the E Max of [met]-enkephalin, DAMGO and morphine ( Fig. 5C and D) , indicating a degree of unsurmountable antagonism by noribogaine in functional assays. Apparent unsurmountable antagonism can encompass several distinct molecular mechanisms such as (a) irreversible competitive antagonism, (b) noncompetitive antagonism, or (c) functional antagonism; for review (Neubig et al., 2003) .
Binding model of noribogaine and ibogaine to the inactive conformation of the mu opioid receptor
Noribogaine showed a profile of unbiased antagonist at the OPRM and stabilized the inactive conformation of the receptor. . Corresponding values of EC 50 , E Max , and K e with mean ± SE for the entire set of experiments can be found in Table 5. Thus, it was possible to use an available crystal structure of the inactive form of the OPRM to perform in silico binding experiments with noribogaine.
We developed an in silico binding model based on the mouse OPRM co-crystal structure [PMID 22437502] (Manglik et al., 2012) as described in methods. The mouse and human OPRM share 94% (global) sequence identity and all binding site residues are identical. After initial optimization of the model, the top docking poses of noribogaine and ibogaine were pharmacophorically aligned with the co-crystal morphinan antagonist as one would expect: the hydrophobic ibogaine and noribogaine bicyclic system and ethyl substituent with morphinan cyclopropyl residues were spatially aligned and the positively charged tertiary amines were superimposed with each forming a hydrogen bond to the site chain of Asp147. Then, the noribogaine and ibogaine OPRM complexes were each used in a 12 ns all atom explicit water molecular dynamics simulation (see methods). Trajectory analysis revealed the most prevalent interactions of noribogaine (Fig. 6A ) and ibogaine. Both ligands formed a stable hydrogen bond with Asp147 via their tertiary amine. Noribogaine and ibogaine formed pi-cation interaction with Tyr148 (64% and 56%, respectively), and hydrophobic interactions with His297 (64 and 93%, respectively). Further hydrophobic interactions were observed between Val236 (~40 and~60%, respectively), Tyr326 (~20 and~40% respectively), Met151 (~20% and~30%, respectively) and also Trp293, Ile296, Val300. Characteristically, noribogaine, but not ibogaine, formed a water bridge with Tyr148 for 34% of the simulation time. Both ligands showed a hydrogen bond with His297 for about 20% of the simulation. Movies of the simulations were generated and are available as supporting material. A representative illustration frame of noribogaine in the OPRM was extracted from the simulation and is shown in Fig. 6B .
Supplementary data related to this article can be found online at http://dx.doi.org/10.1016/j.neuropharm.2015.08.032.
Discussion
Historically, in vivo studies excluded the possibility of prototypical morphine-like agonistic mechanism of ibogaine and its metabolite noribogaine at the mu and/or kappa opioid receptors (see introduction). In the other hand, naloxone-like antagonistic mechanisms could not be demonstrated either. These ambiguous results lead to a gap of knowledge between the correlation of receptor-ligand mechanistics and the intriguing and beneficial effects of ibogaine and its metabolite noribogaine with opiate drugs and to the opioid system. Our current study now demonstrates that noribogaine is in fact a G-protein biased kappa agonist, and a weaker mu antagonist. The described potencies in our study closely match physiologically relevant brain concentrations of therapeutically effective doses of noribogaine. Thus, noribogaine's atypical modulatory properties of the kappa opioid system, and to a certain extend the mu opioid system, in the central nervous system (CNS) must be taken into account for its mechanism of action in vivo.
Our study shows that noribogaine is a kappa agonist. Intravenous noribogaine potently triggered the release of prolactin in rats and it was reported that this effect was centrally mediated (Baumann et al., 2001b) . We propose that noribogaine-induced prolactin release is mediated by central OPRK, similar to what was described for the kappa agonist nalmefene (Bart et al., 2005) . Our data also show that noribogaine was a moderately potent mu antagonist. Thus, noribogaine also belongs to the class of dual agonist/antagonist kappa-mu opioid ligands. In comparison, ibogaine is a more potent mu antagonist and a much weaker kappa agonist than noribogaine. Ibogaine is metabolized to noribogaine in mammals and, as a consequence, the acute and delayed biological effects of ibogaine treatment can be attributed to the ibogainenoribogaine mixture rather than to ibogaine only (Zubaran et al., 1999) . Intermediate levels of drug-related interoceptive stimuli generalization were observed with the mixed action opiates SKF10,047 (79%), pentazocine (74%), nalorphine (70%), and diprenorphine (75%) (Helsley et al., 1998) . These results provide support to the notion that the ibogaine-noribogaine mixture could be recognized as a mixed opioid agonist-antagonist in vivo. 18-MC was a micro-molar non-specific competitive antagonist of the kappa and mu receptors; however it should remain clear that noribogaine belongs to a different class of opioid ligand than ibogaine or 18-MC. In consequence, the in vivo effects of 18-MC, experimentally demonstrated or hoped for, cannot rely on the pharmacological knowledge and demonstrated effects of noribogaine on the opioid system.
A series of studies (see introduction) described the biological effects of noribogaine treatment in reducing the stimulating and reinforcing properties of morphine, possessing a modest analgesic power on its own, and having the capability to potentiate morphine analgesia, especially in morphine tolerant animals. Our study shows that noribogaine inhibited b-arrestin-2 recruitment of both mu and kappa agonists. This could to a certain extent mimic the effects of a functional deletion of the b-arrestin-2 gene which resulted in remarkable potentiation and prolongation of the analgesic effect of morphine in mice (Bohn et al., 1999) . Additionally, it was shown that dynorphin A attenuated morphine tolerance at doses devoid of observable effects on nociception (Schmauss and Herz, 1987; Takemori et al., 1992) . U50,488 also attenuated morphine tolerance and potentiated morphine analgesia in morphine tolerant animals at doses devoid of analgesic activity when co-administrated with morphine (Tao et al., 1994) . Taken together, these studies show that low doses of OPRK agonists can reduce morphine tolerance and desensitization (Sharma and Mediratta, 2001) . Future studies assessing the comparative activity of noribogaine in wild type and genetically modified opioid receptor animal models should provide further understanding of the contribution of the kappa receptors in the effects of noribogaine.
Ultra-low doses of opioid antagonists (naloxone and naltrexone), which selectively inhibit the excitatory effects of opioid agonists, have been reported to augment systemic morphine analgesia and inhibit the development of tolerance/physical dependence (Powell et al., 2002) . In vitro assays demonstrated that these phenomena are reproducible at the cellular level where ultralow concentrations of opioid ligand effectively synergized the binding and functional response of agonists via OPRM-OPRD heteromers (Gomes et al., 2011) . In this regard, the moderate OPRM inhibitory activity of noribogaine at moderate to low therapeutic doses could be of biological relevance and warrants further investigation at the molecular level on OPRM-OPRD heteromers.
In line with their localization in the hippocampus, amygdala, hypothalamus, striatum and spinal cord, the function of the kappa opioid receptors are related to learning and memory, emotional control, stress response and pain (Bruchas et al., 2010; Butelman et al., 2012; Schwarzer, 2009) . Kappa agonists hold therapeutic potential for mood and addiction disorders, psychiatric comorbidities, and pain management, however they also induce undesirable on-target side effects such as place aversion, dysphoria and anhedonia; and hallucinations at high doses. On the other hand, kappa antagonists hold therapeutic potential as antidepressants and anxiolytics, but may induce hyperalgesic states. Thus, until recently, kappa ligands were not considered for therapeutic development due to their undesirable side effects. This view changed with the introduction of a more elaborate understanding of ligand-receptor pharmacology and the characterization of receptor drugs exhibiting functional selectivity, for review (Violin et al., 2014) . As reviewed in (Kyle, 2013) , certain opioid ligands were reported to be G protein-biased agonists, notably at the mu receptor, and exhibited interesting physiological properties (Rives et al., 2012) .
Recent elegant studies in rodents have mechanistically linked the activation of p38 MAPK to stress-mediated OPRK stimulation via the b-arrestin mediated transduction pathway (Bruchas et al., 2007 (Bruchas et al., , 2006 . In this frame, G-protein biased kappa agonists were described as hypothetical analgesic drugs without aversive and dysphoric components (Chavkin, 2011) . In our study, noribogaine exhibited a profound functional bias and was not an agonist of the OPRK b-arrestin pathway. Therefore, noribogaine appears to carry the prerequisite pharmacological characteristics of an analgesic kappa opioid drug devoid of aversive and dysphoric effects which may become important during opiate detoxification and painful states.
Our study also shows that noribogaine is a b-arrestin biased kappa antagonist, more potent and efficacious at inhibiting agonistinduced signaling to this pathway than to the G-protein pathway. At a concentration corresponding to levels in the brain of rats (e.g. 0.5e5 mM) several hours after noribogaine dosing in animals (Pearl et al., 1997) , or days after ibogaine treatment in humans (Mash et al., 2000) , noribogaine tested in vitro preserved the signaling of dynorphin A to the G-protein pathway while markedly inhibiting barrestin recruitment. Thus noribogaine in the presence of dynorphin was able to modulate the functional selectivity of dynorphin. This peculiar pharmacological property could contribute to antagonist-like anti-depressive and anxiolytic activities against stress-induced and over-active dynorphin/kappa system, as seen during drug dependence, drug withdrawal and cravings. This functionally selective inhibitory kappa activity may also mediate positive effects against stress and anxiety, and atypical depression that will be considered in future studies.
Ligand-induced functional selectivity of otherwise unbiased agonists was previously demonstrated for some receptors of the GPCR family interactions with conformation-specific allosteric modulators of the receptors (i.e. the allosteric ligand LPI805 for the NK2 receptor (Maillet et al., 2007) ; for review (Kenakin, 2007) ). However, in the present study noribogaine does not appear to be an allosteric ligand: 1) it directly competed with the binding of orthosteric radiolabeled agonists DAMGO, U69,593; 2) it displayed functional competitive behavior with opioid orthosteric antagonists in GTPgS assays; 3) it was docked to the morphinan orthosteric binding site of the OPRM inactive state in silico with good stringency: in silico binding experiments provide basis for noribogaine's interacting moieties with the inactive conformational state crystal structure of the mu receptor and in silico interaction scores of noribogaine and ibogaine are congruent to their affinity ranking in in vitro radioligand assays. In fact, our data suggest that noribogaine would induce functional selectivity to dynorphin A via the interplay of a set of active and inactive conformational states. Certain conformations would be easily accessible to other agonists (e.g. the inactive conformations and active G-protein conformations) and other conformations would be energetically challenging to populate in place of noribogaine (e.g. the non-recruiting barrestin conformation).
Multiple studies provide evidence for the existence of intermediate conformational states linking the inactive receptor to the fully active receptor. Agonist binding and activation of GPCRs has been proposed to occur through a multistep process; for review (Kobilka, 2004) . The intermediate conformational states generated during multistep agonist binding may have unique functional properties as it is known that GPCR can couple to different Gproteins and also activate non-G protein dependent pathways depending on their conformational state(s); for review (Kenakin, 2007) . Interestingly, recent investigations in drug design described an allotropic binding mode for certain OPRK agonists, which encompassed sequential drugereceptor interaction mechanisms . In this regard, noribogaine merits further investigation at a deeper molecular level using discrete drugereceptor interactions and conformational dynamic designs as well as cellular designs to assess further these potential allotropic binding modalities and their functional consequences.
Conclusion
This study shows that noribogaine is a dual ligand of both mu and kappa opioid receptors. Noribogaine exhibits a profound Gprotein biased agonism at the opioid receptors and can modulate dynorphin signaling via the kappa receptor. This study clarifies the mechanisms of noribogaine at modulating the function of opioid receptors at the cellular level, providing ground for explanatory mechanisms at the opioid system in vivo as well as new avenues of therapeutic development and applicability. 
